Corporate Directors Forum Names NuVasive(R) Board Member as Director of the Year

Corporate Directors Forum Names NuVasive(R) Board Member as Director of the Year 
SAN DIEGO, CA -- (Marketwired) -- 09/19/13 --   NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
is proud to announce that the Corporate Directors Forum (CDF) named
the Company's long-standing board member, Jack Blair, as Director of
the Year for Corporate Governance at an awards ceremony on September
18th. 
Each year, the CDF honors San Diego's top directors who exhibit
outstanding performance. The corporate governance award is bestowed
upon a leader that has exceptionally guided the board of directors
and executive management of a growing company while maintaining the
ethics and integrity of the board. 
NuVasive Director Jack Blair said, "Being named Director of the Year
is both a humbling and gratifying experience. As a director of
NuVasive, I am extremely proud to have played a part in the growth
and success of a company that is improving spine patient outcomes
globally. The award suggests that my fellow directors and the
NuVasive management team appreciate my service, contributions, and
commitment to our strategic mission. I am truly honored and wish to
thank all of my colleagues for their support." 
Jack Blair has been a member of the NuVasive board of directors since
August 2001. Throughout his career, Blair has served in various
capacities with Smith & Nephew, PLC, and Richards Medical Company.
Most recently he was Group President of Smith & Nephew's North and
South American and Japanese operations. Until November 2007, Blair
served as Chairman of the board of directors of DJO Inc., an
orthopaedic company. Blair holds a Bachelor of Arts Degree in
Government from Miami University and a Master of Business
Administration from the University of California, Los Angeles.  
Alex Lukianov, NuVasive Chairman and Chief Executive Officer, said,
"Jack Blair has been instrumental in guiding NuVasive in our mission
to change spine surgery since he was named to the board of directors
in 2001. We are very pleased that Jack's service is being formally
recognized, and I look forward to his continued contribution in our
drive toward becoming a $1 Billion Start-up(TM)."  
Collectively, the NuVasive board of directors has received several
prestigious awards, including the CDF Director of the Year and Ernst
& Young's Entrepreneur of the Year. Chairman and Chief Executive
Officer, Alex Lukianov, was named the 2011 Director of the Year in
Corporate Citizenship and received the 2009 Entrepreneur of the Year
National Award in Health Sciences. Mr. Lesley Howe was recognized for
a 2008 Lifetime Achievement Award in Corporate Governance, and Mr.
Peter Farrell, Ph.D., AM, received the 2005 United States
Entrepreneur of the Year National Award in Health Sciences. 
About the Corporate Directors Forum (CDF)
 Corporate Directors Forum
is a nonprofit organization located in San Diego. CDF is the largest
regional association of corporate directors in the U.S. and offers
regular, interactive education programs for directors, officers and
business leaders. CDF's purpose is to help directors be better
directors through director education and peer-to-peer networking. 
For more information on the NuVasive board of directors visit:
http://Ez.com/NUVABoard  
For NuVasive press materials please visit:
http://www.nuvasive.com/about-us/newsroom/  
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally-integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of more than 80
unique products developed to improve spine surgery and patient
outcomes. The Company's principal procedural solution is its Maximum
Access Surgery, or MAS(R), platform for lateral spine fusion. MAS was
designed to provide safe, reproducible, and clinically proven
outcomes, and is a highly differentiated solution with fully
integrated neuromonitoring, customizable exposure, and a broad
offering of application-specific implants and fixation devices
designed to address a variety of pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game-changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
worldwide. NuVasive is focused on becoming a $1 Billion Start-up(TM);
taking market share by maintaining a commitment to Superior Clinical
Outcomes, Speed of Innovation(R), and Absolute Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to those
risks and uncertainties more fully described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2408655 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com  
Media Contact: 
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com